Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

In- class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

Joshua Richter, Saulius Girnius, Ruemu Birhiray, Eric Lloyd, Dasha Cherepanov, Stephen J. Noga, Isabel Nascimento-Ferreira, Robert Rifkin

Blood (2024) 144 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2024-194592

Published: 2024

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

Blood (2017) 130 (Supplement 1): 5419.

https://doi.org/10.1182/blood.V130.Suppl_1.5419.5419

Published: 2017

Journal Articles

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, Saulius Girnius, MD, Saurabh Chhabra, MD, Robert Frank Cornell, MD, Cristina J. Gasparetto, MD, Chatchada Karanes, MD, Matthew A. Lunning, DO, Jeffrey V. Matous, MD, Ruben Niesvizky, MD, Chaim Shustik, MD, Robert K. Stuart, MD, Jason Lih, PhD, Yihua Lee, PhD, Zeena Salman, Thorsten Graef, MD PhD, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 3111.

https://doi.org/10.1182/blood.V130.Suppl_1.3111.3111

Published: 2017

Journal Articles

Low-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As an Efficacious and Safe Peripheral Blood Stem Cell Mobilizing Regimen in Patients with Hematologic Malignancies

Arun Sendilnathan, MD, Jaskirat Singh Randhawa, MD, Changchun Xie, Rebecca Bolt, RN, Thomas Leemhuis, Nora Buzek, Kitty Tierney, Susan Pinkard, Saulius Girnius, MD, Stephen Medlin, DO, FACP

Blood (2015) 126 (23): 5438.

https://doi.org/10.1182/blood.V126.23.5438.5438

Published: 2015

Journal Articles

Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A

Muhammad Kashif Riaz, MD, Saulius Girnius, MD, Joseph Edward Palascak, MD FACP

Blood (2015) 126 (23): 4676.

https://doi.org/10.1182/blood.V126.23.4676.4676

Published: 2015

Journal Articles

Evaluating the Efficacy and Toxicity of Two Lenalidomide Dose Regimens for the Treatment of Older Relapsed Multiple Myeloma Patients with Co-Morbidities: A Multi-Site Study at the Veteran's Administration Hospitals

Sarvari V Yellapragada, MD, Shayna Sarosiek, MD, Neelima D Prabhala, B.A., Mehmet Kemalsamur, PhD, Antoun Houranieh, RPh., M.S., PhD, Saulius Girnius, MD, Praveen Tumula, MD, Suman Kambhampati, MD, Nirmala Bhoopalam, MD, Rao H Prabhala, PhD, David Roodman, MD, PhD, Alan Lichtenstein, MD, Nikhil C Munshi, MD

Blood (2015) 126 (23): 5370.

https://doi.org/10.1182/blood.V126.23.5370.5370

Published: 2015

Journal Articles

Suppression Of Uninvolved Immunoglobulin Has Significant Clinical Implication Including Predicting Relapse In Multiple Myeloma

Saulius Girnius, M.D., Rachel Neuwirth, Ph.D, Dixie-Lee Esseltine, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Munshi C Nikhil, MD

Blood (2013) 122 (21): 3151.

https://doi.org/10.1182/blood.V122.21.3151.3151

Published: 2013

Journal Articles

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

Saulius Girnius, M.D., David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, John L Berk, MD, Frederick L Ruberg, MD, Hans Meier-Ewert, MD, Vaishali Sanchorawala, MD

Blood (2011) 118 (21): 2043.

https://doi.org/10.1182/blood.V118.21.2043.2043

Published: 2011

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Saulius Girnius, MD, Frank Tsai, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Lisa Yanarella, NP, Kathleen T. Finn, NP, Nancy T. Andrea, MD, John Mark Sloan, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4352.

https://doi.org/10.1182/blood.V114.22.4352.4352

Published: 2009

Journal Articles

Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.

Saulius Girnius, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Kathleen T. Finn, NP, Nancy T. Andrea, MD, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4356.

https://doi.org/10.1182/blood.V114.22.4356.4356

Published: 2009

Journal Articles

Melphalan, Lenalidomide, and Dexamethasone Combination Therapy in Patients with AL Amyloidosis.

John Mark Sloan, MD, Vaishali Sanchorawala, MD, Saulius Girnius, M.D., Kathleen T. Finn, NP, David C. Seldin, MD, PhD

Blood (2009) 114 (22): 1859.

https://doi.org/10.1182/blood.V114.22.1859.1859

Published: 2009

Journal Articles

Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.

Saulius Girnius, MD, David C. Seldin, MD, PhD, Martha Skinner, MD, Kathleen T. Finn, NP, Vaishali Sanchorawala, MD

Blood (2007) 110 (11): 2873.

https://doi.org/10.1182/blood.V110.11.2873.2873

Published: 2007

NARROW

In- class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Low-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As an Efficacious and Safe Peripheral Blood Stem Cell Mobilizing Regimen in Patients with Hematologic Malignancies

Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A

Evaluating the Efficacy and Toxicity of Two Lenalidomide Dose Regimens for the Treatment of Older Relapsed Multiple Myeloma Patients with Co-Morbidities: A Multi-Site Study at the Veteran's Administration Hospitals

Suppression Of Uninvolved Immunoglobulin Has Significant Clinical Implication Including Predicting Relapse In Multiple Myeloma

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.

Melphalan, Lenalidomide, and Dexamethasone Combination Therapy in Patients with AL Amyloidosis.

Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only